1. Design, synthesis, and cytotoxicity of stabilized mycolactone analogs
- Author
-
Ya Zhou, Vaddela Sudheer Babu, and Yoshito Kishi
- Subjects
Buruli ulcer ,Cell Survival ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Antineoplastic Agents ,010402 general chemistry ,medicine.disease_cause ,01 natural sciences ,Biochemistry ,Cell Line ,Inhibitory Concentration 50 ,Mice ,chemistry.chemical_compound ,Cell Line, Tumor ,Drug Discovery ,Carcinoma ,medicine ,Animals ,Humans ,Potency ,Mycolactone ,Cytotoxicity ,Molecular Biology ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Toxin ,Organic Chemistry ,medicine.disease ,Cycloaddition ,0104 chemical sciences ,Cell culture ,Drug Design ,Molecular Medicine ,Macrolides - Abstract
On exposure to visible light, mycolactone A/B, the causative toxin of Buruli ulcer, rearranges to a mixture of four photo-mycolactones apparently via a rare photochemically-induced [4πs + 2πa] cycloaddition. In order to prevent the rearrangement, two C6′-C7′ dihydromycolactone analogs 6′α-15 and 6′β-15 were designed and synthesized. 6′α-15 and 6′β-15 were shown to be stable under not only photochemical, but also acidic and basic conditions. Cytotoxicity was tested against arbitrarily chosen four cell lines (human Hek-293, human lung carcinoma A-549, human melanoma LOX-IMVI, and mouse L-929), thereby revealing that: (1) both analogs maintain potent cytotoxicity; (2) 6′β-15 exhibits significantly higher potency against human cell lines than 6′α-15; (3) in comparison with parent mycolactone A/B, 6′β-15 exhibits equal potency against human Hek-293, whereas significantly lower potency against human lung carcinoma A-549 and human melanoma LOX-IMVI.
- Published
- 2017
- Full Text
- View/download PDF